S26-240 Targeted Modulation of SNAP23 for Treatment of RAS-Driven Cancers via Engineered Proteases, Heterobifunctional Small Molecules (PROTACs and RIPTACs), and Antibody-Conjugated Delivery KRAS mutations drive roughly a quarter of all human cancers, yet approved KRAS inhibitors deliver only short-lived responses before resistance emerges, and combination strategies have been limited by severe toxicity. Yonglu Che Paul Khavari